CRISPR Webinar

CRISPR & Gene Editing - The Next Industrial Revolution (XDNA Index)

Streaming On Demand

What distinguishes this industrial revolution, from the previous, is that it will be predicated by the changes in life sciences and healthcare due to CRISPR and genomic editing. The Strategic CRISPR & Gene Editing Technology Index ( XDNA Index) is designed to capitalize on the next generation of healthcare by providing access to over twenty-five CRISPR & Gene Editing companies.

Investor Research

INDEX DETAILS

Index Name
Strategic CRISPR & Gene Editing Technology Index
Weighting Method
Modified Market Cap
Rebalance
Quarterly
Number of Constituents
20-30

Documents

XDNA Investor Presentation
Download
XDNA Fact Sheet
Download

WATCH THE CRISPR WEBINAR HERE

CRISPR & The Next Industrial Revolution Outlook

A pivotal event just happened in the fourth industrial revolution as The CIA Just Invested in Woolly Mammoth Resurrection Technology (a CRISPR start-up) and the White House issued an Executive Order, “to develop genetic engineering technologies and techniques.”

What distinguishes this industrial revolution, from the previous, is that it will be predicated by the changes in life sciences and healthcare due to CRISPR and genomic editing. The Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA) is designed to capitalize on the next generation of healthcare by investing in over twenty-five CRISPR & Gene Editing companies.

Throughout history, society has been transformed through the industrial revolutions. The previous industrial revolutions focused on the impact that technology has on our resources: agriculture, energy, metallurgy, textiles, chemicals, and transportation. Participants will learn how the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA) is designed to capitalize on the next generation of healthcare by investing in CRISPR & Gene Editing companies disrupting the genomic and life science industries.

Participants will learn:

  • What is CRISPR & Gene Editing Technology
  • 2023 Catalysts
  • The Future of Gene Editing and Data due in 2023
  • The Publicly Traded Companies
  • The CRISPR & Gene Editing Sub-Sectors: CRISPR & Gene Editing Technology, Gene Editing Development Solutions, Gene Editing Sequencing Solutions
  • How to Implement the Kelly CRISPR & Gene Editing Technology ETF (Nasdaq: XDNA)

It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. Strategic Investments does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index. Strategic Investments licenses its indices to third parties for the creation of investment funds or other vehicles, such as exchange-traded funds (ETFs), exchange-traded notes (ETNs), institutional asset mandates, and structured notes.

The information contained does not reflect the performance of any fund or account managed or serviced by Strategic Investments, and there is no guarantee that investors will experience the type of performance reflected above. There is no guarantee that any historical trend illustrated herein will be repeated in the future, and there is no way to predict precisely when such a trend will begin. There is no guarantee that any market forecast made in this commentary will be realized. The mention of specific securities is not a recommendation or solicitation for any person to buy, sell or hold any particular security and should not be relied upon as investment advice. The views and opinions in the preceding commentary are as of the date of publication and are subject to change without notice. This material represents an assessment of the market environment at a specific point in time, should not be relied upon as investment advice, is not intended to predict or depict performance of any investment and does not constitute a recommendation or an offer for a particular security. We consider the information in this presentation to be accurate, but we do not represent that it is complete or should be relied upon as the sole source of suitability for investment.